What type of study is this?

This is a Meta-Analysis study (also classified as: Pre-Registered Trial, Systematic Review).

What question did this study set out to answer?

This meta-analysis aimed to assess the efficacy and safety of TACE combined with immunotherapy and targeted therapy in unresectable hepatocellular carcinoma.

November 1, 2025Therapeutic Advances in GastroenterologyOpen Access

Transarterial chemoembolization combined with immunotherapy and targeted therapy as first-line treatment for unresectable and non-metastatic hepatocellular carcinoma: a meta-analysis of phase III trials

View Full Paper

Ask AI

Bookmark

Authors

LWLichao Wang BLBo Luo MZMingrui Zhao

Discussion

Member takes

Implication

Meta-analysis reveals TACE with immunotherapy increases progression-free survival and response rates in unresectable HCC, indicating potential benefits despite higher adverse events.

Key Points

This meta-analysis aimed to assess the efficacy and safety of TACE combined with immunotherapy and targeted therapy in unresectable hepatocellular carcinoma.
Systematic review and meta-analysis of phase III RCTs like EMERALD-1, LEAP-012, and TALENTACE.
Data sources included PubMed and conference proceedings until July 6, 2025.
Pooled HRs for progression-free survival and ORs for objective response rates were calculated.
Combination therapy showed a significant improvement in progression-free survival with a pooled HR of 0.69.
The objective response rate increased with a pooled OR of 1.83, reflecting better tumor response.
Increased toxicity was observed, with a higher incidence of grade 3-5 adverse events and serious AEs.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/6925437fc0ce034ddc358e59 https://doi.org/10.1177/17562848251396424

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis reveals TACE with immunotherapy increases progression-free survival and response rates in unresectable HCC, indicating potential benefits despite higher adverse events.

Transarterial chemoembolization combined with immunotherapy and targeted therapy as first-line treatment for unresectable and non-metastatic hepatocellular carcinoma: a meta-analysis of phase III trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Transarterial chemoembolization combined with immunotherapy and targeted therapy as first-line treatment for unresectable and non-metastatic hepatocellular carcinoma: a meta-analysis of phase III trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider